A potentially immunologically inert derivative of the reverse tetracycline-controlled transactivator

Biotechnology Letters

Volumn 32, Issue 6, 2010, Pages 749-754

  Zaldumbide, Arnaud ^a   Weening, Susan ^a   Cramer, Steve J ^a   Rabelink, Martijn J W E ^a   Verhaagen, Joost ^b   Hoeben, Rob C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Doxycycline; Gene therapy; Inducible expression; Promoter; Transcription

Indexed keywords

ANTIGENIC PEPTIDES; DOXYCYCLINE; EPSTEIN-BARR VIRUS; FUSION PROTEINS; HETEROLOGOUS GENES; IMMUNE RESPONSE; INDUCIBLE EXPRESSION; MAMMALIAN CELLS; TRANSACTIVATORS;

GENE THERAPY; GENETIC ENGINEERING; IMMUNOLOGY; MAMMALS; PROTEINS; TRANSCRIPTION; VIRUSES;

GENE EXPRESSION REGULATION;

EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN CLASS 1; HYBRID PROTEIN; TETRACYCLINE; TRANSACTIVATOR PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; BIOSYNTHESIS; CELL LINE; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETICS; HUMAN; IMMUNE EVASION; IMMUNOLOGY; METABOLISM;

ANTIGEN PRESENTATION; CELL LINE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; RECOMBINANT FUSION PROTEINS; TETRACYCLINE; TRANS-ACTIVATORS;

HUMAN HERPESVIRUS 4; MAMMALIA;

EID: 77952160858     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-010-0218-8     Document Type: Article

References (19)

1. Albanese C, Hulit J, Sakamaki T et al (2002) Recent advances in inducible expression in transgenic mice. Semin Cell Dev Biol 13: 129-141.
2. Blake N, Lee S, Redchenko I et al (1997) Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (gly-ala)-containing protein requires exogenous processing. Immunity 7: 791-802.
3. Carlotti F, Bazuine M, Kekarainen T et al (2004) Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. Mol Ther 9: 209-217.
4. Chenuaud P, Larcher T, Rabinowitz JE et al (2004) Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther 9: 410-418.
5. Daskalogianni C, Apcher S, Candeias MM et al (2008) Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing. J Biol Chem 283: 30090-30100.
6. Eggers R, Hendriks WT, Tannemaat MR et al (2008) Neuroregenerative effects of lentiviral vector-mediated GDNF expression in reimplanted ventral roots. Mol Cell Neurosci 39: 105-117.
7. Favre D, Blouin V, Provost N et al (2002) Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 76: 11605-11611.
8. Gossen M, Freundlieb S, Bender G et al (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769.
9. Hendriks WT, Eggers R, Carlstedt TP et al (2007) Lentiviral vector-mediated reporter gene expression in avulsed spinal ventral root is short-term, but is prolonged using an immune "stealth" transgene. Restor Neurol Neurosci 25: 585-599.
10. Hoyt MA, Zich J, Takeuchi J et al (2006) Glycine-alanine repeats impair proper substrate unfolding by the proteasome. EMBO J 25: 1720-1729.
11. Karttunen J, Sanderson S, Shastri N (1992) Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 89: 6020-6024.
12. Latta-Mahieu M, Rolland M, Caillet C et al (2002) Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 13: 1611-1620.
13. Levitskaya J, Sharipo A, Leonchiks A et al (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 94: 12616-12621.
14. Ossevoort M, Zaldumbide A, Cramer SJ et al (2006) Characterization of an immuno 'stealth' derivative of the herpes simplex virus thymidine-kinase gene. Cancer Gene Ther 13: 584-591.
15. Sharipo A, Imreh M, Leonchiks A et al (2001) cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. FEBS Lett 499: 137-142.
16. Urlinger S, Baron U, Thellmann M et al (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 97: 7963-7968.
17. Yin Y, Manoury B, Fahraeus R (2003) Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301: 1371-1374.
18. Zaldumbide A, Hoeben RC (2008) How not to be seen: immune-evasion strategies in gene therapy. Gene Ther 15: 239-246.
19. Zaldumbide A, Ossevoort M, Wiertz EJ et al (2007) In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpes virus. Mol Immunol 44: 1352-1360.